NDC Package 51817-586-01 Bortezomib

Injection, Powder, Lyophilized, For Solution Intravenous; Subcutaneous - View Billable Units, 11-Digit Format, RxNorm

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
51817-586-01
Package Description:
1 VIAL in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL
Product Code:
Proprietary Name:
Bortezomib
Non-Proprietary Name:
Bortezomib
Substance Name:
Bortezomib
Usage Information:
This medication is used to treat certain types of cancer (such as multiple myeloma, mantle cell lymphoma). It works by slowing or stopping the growth of cancer cells.
11-Digit NDC Billing Format:
51817058601
NDC to RxNorm Crosswalk:
  • RxCUI: 402243 - bortezomib 3.5 MG Injection
  • Product Type:
    Human Prescription Drug
    Labeler Name:
    Pharmascience Inc.
    Dosage Form:
    Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
    Administration Route(s):
  • Intravenous - Administration within or into a vein or veins.
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
  • Active Ingredient(s):
    Sample Package:
    No
    FDA Application Number:
    ANDA208392
    Marketing Category:
    ANDA - A product marketed under an approved Abbreviated New Drug Application.
    Start Marketing Date:
    05-02-2022
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 51817-586-01?

    The NDC Packaged Code 51817-586-01 is assigned to a package of 1 vial in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial of Bortezomib, a human prescription drug labeled by Pharmascience Inc.. The product's dosage form is injection, powder, lyophilized, for solution and is administered via intravenous; subcutaneous form.

    Is NDC 51817-586 included in the NDC Directory?

    Yes, Bortezomib with product code 51817-586 is active and included in the NDC Directory. The product was first marketed by Pharmascience Inc. on May 02, 2022 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the 11-digit format for NDC 51817-586-01?

    The 11-digit format is 51817058601. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-3-251817-586-015-4-251817-0586-01